Apr 09, 2020
Roche's Ocrevus Continues to Impress in the EU with Strong Uptake in New Start and Switch Multiple Sclerosis Patient Segments, but Novartis' Mayzent and Ofatumumab May Threaten the Brand's Long-Term Dominance
Mar 10, 2020
2020 Disease Analysis: Multiple Sclerosis - Sanofi to Co-Develop Digital Therapeutic for MS Patients
Oct 07, 2019
Benefitting From Expanded Access in Europe, Roche's Ocrevus is on Track to Displace Biogen's Tysabri in Neurologist Preference and Share Among Patients with Relapsing Forms of Multiple Sclerosis Over the Next Six Months
Oct 09, 2018
Uptake of Biogen's Tecfidera and Increased Availability of Merck KGaA's Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva's Copaxone
Mar 27, 2018
Uptake of Merck KGaA's Mavenclad in the European Multiple Sclerosis Market Currently Stalled Due to Restrictive Guidelines and Pending Additional Country-Level Approvals
Feb 06, 2018
British Columbia includes (Pr)LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients
Jan 10, 2018
Use of Monoclonal Antibody Disease-Modifying Therapies on the Rise in Multiple Sclerosis, Fueled Largely by the Introduction of Genentech's Ocrevus
Nov 15, 2017
Advanced Practice Providers Treat Significantly More of their Multiple Sclerosis Patients with Monoclonal Antibody Disease-Modifying Therapies Compared to Neurologists in the US
Sep 19, 2017
New Review Considers Selective Targeting of T and B Cell Populations by Alemtuzumab in the Treatment of Multiple Sclerosis
Aug 01, 2017
Prince Edward Island includes LEMTRADA® (alemtuzumab) on provincial drug program for eligible patients